Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder

Fineline Cube Jun 17, 2026
Company Drug

Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang

Fineline Cube Jun 17, 2026
Company Deals Digital

Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion

Fineline Cube Apr 14, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...

Company Drug

Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA

Fineline Cube Apr 14, 2023

Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...

Company Deals

Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions

Fineline Cube Apr 14, 2023

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...

Company Drug

Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors

Fineline Cube Apr 14, 2023

The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics

Fineline Cube Apr 14, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...

Company R&D

HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency

Fineline Cube Apr 14, 2023

HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...

Company Deals

Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion

Fineline Cube Apr 14, 2023

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed...

Company

Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022

Fineline Cube Apr 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...

Company

BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil

Fineline Cube Apr 14, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...

Company R&D

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

Fineline Cube Apr 13, 2023

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...

Company Drug

Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma

Fineline Cube Apr 13, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...

Company Deals

VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy

Fineline Cube Apr 13, 2023

New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...

Company Deals

Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing

Fineline Cube Apr 13, 2023

Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...

Company Drug

Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL

Fineline Cube Apr 13, 2023

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...

Company Drug

Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China

Fineline Cube Apr 13, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...

Company Drug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

Fineline Cube Apr 13, 2023

China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...

Company Medical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Fineline Cube Apr 12, 2023

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...

Company Drug

Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment

Fineline Cube Apr 12, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...

Company Drug

Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G

Fineline Cube Apr 12, 2023

Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...

Company Drug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

Fineline Cube Apr 12, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...

Posts pagination

1 … 556 557 558 … 684

Recent updates

  • GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder
  • Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang
  • Bayer AG Inaugurates Second Consumer Health Innovation Center in China, Expanding Skin and Digestive Health Partnerships
  • Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy
  • Shanghai Henlius Biotech’s HLX04-O Meets Primary Endpoints in Phase III Trial for Wet AMD, Demonstrating Non-Inferiority to Ranibizumab
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder

Company Drug

Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang

Company

Bayer AG Inaugurates Second Consumer Health Innovation Center in China, Expanding Skin and Digestive Health Partnerships

Company Drug

Shanghai Henlius Biotech Receives Australian Clearance for Phase II Study of PD-L1 ADC HLX43 Combined with Hansizhuang in NSCLC Neoadjuvant Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.